Memantine: legal
This page summarises memantine's status in the places checked; it is not legal advice, and it does not cover every country or state.
United States
Memantine is an approved prescription medicine. The FDA records that Namenda tablets “are the subject of NDA 021487 held by AbbVie Inc. and initially approved on October 16, 2003”, and that “Namenda is indicated for the treatment of moderate to severe dementia of the Alzheimer's type”.[1] The brand tablets are now discontinued; in September 2026 the FDA determined they “were not withdrawn from sale for reasons of safety or effectiveness”, which lets generic versions keep being approved.[1] Use for memory or tolerance outside that indication is off-label, and the drug still needs a prescription.
Memantine does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[2] State law was not checked for this page.
Sport
The World Anti-Doping Agency's list, which states “This List shall come into effect on 1 January 2026.”, does not name memantine.[3]
References
- Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (FR Doc. 2026-17812, 1 September 2026) — Food and Drug Administration, Federal Register
- 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
- World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency
Comments
Sign in to join the conversation.
No comments yet.